DFCI OncoPanel 3 (DFCI-ONCOPANEL-3)

Overview

DFCI OncoPanel 3 is a targeted DNA sequencing panel developed at Dana-Farber Cancer Institute (DFCI) / Brigham and Women’s Hospital (BWH). It is used clinically and in research settings for comprehensive cancer genomic profiling, detecting somatic mutations, copy number alterations, and structural variants across a defined set of cancer-relevant genes. Sequencing and analysis are performed at the Center for Advanced Molecular Diagnostics (CAMD) at Brigham and Women’s Hospital.

Used by

• Used to provide genomic characterization of sarcoma specimens in the UCLA biobank / patient-derived tumor organoid (PDTO) “mini-ring” drug sensitivity study PMID:39305899.

Notes

• Targeted hybridization-capture DNA panel; sequencing performed at Brigham CAMD.
• Applied to bone and soft-tissue sarcoma specimens from 126 patients (194 specimens across 24 subtypes) as part of a functional precision medicine platform study PMID:39305899.
• Complemented by whole-genome-seq and bulk rna-seq in the same sarcoma cohort.

Sources

• PMID:39305899 — Al Shihabi et al. used DFCI-ONCOPANEL-3 at Brigham CAMD for targeted DNA panel sequencing of sarcoma specimens (n=194 from 126 patients spanning 24 bone and soft-tissue subtypes); genomic profiling complemented functional PDTO drug-sensitivity screening and whole-genome sequencing; actionable genomic alterations detected in ~30% of patients PMID:39305899.

This page was processed by entity-page-writer on 2026-05-01.